International Multicenter Cohort Study on Beta-Blocker-Free Treatment Strategies for Catecholaminergic Polymorphic...

Area of Science:

• Cardiology
• Genetics
• Pharmacology

Background:

• Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare, life-threatening genetic heart condition.
• Nonselective beta-blockers (BBs) are standard for managing CPVT, but some patients experience adverse effects.
• Alternative treatment strategies are needed for patients intolerant to BBs.

Purpose of the Study:

• To review BB-free treatment options and outcomes in CPVT patients.
• To analyze data from the International CPVT Registry for BB-free strategies.
• To identify effective BB-free configurations for CPVT management.

Main Methods:

• Inclusion of RYR2 variant-positive CPVT patients on BB-free treatment for ≥6 months from the International CPVT Registry.
• Categorization into two groups: intentional nontherapy (INT) for very low-risk patients and alternative strategies for BB-intolerant patients.
• Analysis of treatment strategies including flecainide monotherapy and left cardiac sympathetic denervation.

Main Results:

• 10% of 1,017 CPVT patients (100 individuals) utilized a BB-free strategy.
• 73 patients were in the INT group, primarily asymptomatic low-risk individuals.
• 27 patients received alternative BB-free strategies (flecainide, sympathetic denervation, or both), with only 2 events during a 6-year median follow-up.

Conclusions:

• While BBs are primary for CPVT, 10% of patients require BB-free approaches.
• Careful risk stratification enables the development of safe and effective BB-free treatment plans.
• BB-free strategies offer a viable alternative for select CPVT patients.